DOW JONES26,957.59-123.77 -0.46%
S&P 5003,116.39-11.82 -0.38%
NASDAQ8,980.78+15.16 0.17%

Amicus Therapeutics Sees Prelim. 2020 Galafold Revenue $250M-$260M; Sees FY19 Adj. Operating Expense $410M-$420M

Full-Year 2019 Financial Summary and 2020 Guidance Amicus previously announced full-year 2019 revenue of approximately $181 million (preliminary and unaudited) from commercial sales of Galafold. For the full-year

Benzinga · 01/13/2020 12:09

Full-Year 2019 Financial Summary and 2020 Guidance

Amicus previously announced full-year 2019 revenue of approximately $181 million (preliminary and unaudited) from commercial sales of Galafold.

For the full-year 2020, the Company anticipates total Galafold revenue of $250 million to $260 million based on the average exchange rates for 2019. Growth in 2020 is expected to be driven by continued growth in EU markets, further success from launches in the U.S. and Japan, as well as reimbursement in additional markets. Non-GAAP operating expense guidance for the year is $410 million to $420 million, driven by continued investment in the global Galafold launch, AT-GAA clinical studies, and advancing our gene therapy pipeline.

Cash, cash equivalents, and marketable securities totaled over $450 million (preliminary and unaudited) at December 31, 2019.  The current cash position is anticipated to fund ongoing operations well into 2022.